TGF-β1 expression is detected immunohistochemically in about 40% of PDACs, and high TGF-β1 plasma levels have been measured in HCC patients compared to patients with cirrhosis only, with decreasing levels in patients who underwent effective HCC therapy[12-15]. Here, TGFB1 is linked to hepatocellular carcinoma.